Lv6
3190 积分 2024-07-26 加入
Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody–Drug Conjugate LR-DM1 for Pancreatic Cancer
3天前
已完结
Antibody drug conjugates beyond cytotoxic payloads
3天前
已完结
The medicinal chemistry evolution of antibody–drug conjugates
3天前
已完结
Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC)
3天前
已完结
Engineered exosomes: a transformative therapeutic modality
17天前
已完结
Stalled molecular motor inhibits tumour growth
3个月前
已完结
Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC
3个月前
已完结
Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery
5个月前
已完结
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
5个月前
已完结
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
5个月前
已完结
皖公网安备34019202002308
